Secukinumab treatment of hidradenitis suppurativa: questions remain
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Standard
Secukinumab treatment of hidradenitis suppurativa : questions remain. / Maul, Julia Tatjana; Kolios, Antonios G.A.; Thomsen, Simon Francis; Ring, Hans Christian.
I: The Lancet, Bind 403, Nr. 10427, 2024, s. 616-617.Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
Maul, JT, Kolios, AGA, Thomsen, SF & Ring, HC 2024, 'Secukinumab treatment of hidradenitis suppurativa: questions remain', The Lancet, bind 403, nr. 10427, s. 616-617. https://doi.org/10.1016/S0140-6736(23)01616-1
APA
Maul, J. T., Kolios, A. G. A., Thomsen, S. F., & Ring, H. C. (2024). Secukinumab treatment of hidradenitis suppurativa: questions remain. The Lancet, 403(10427), 616-617. https://doi.org/10.1016/S0140-6736(23)01616-1
Vancouver
Maul JT, Kolios AGA, Thomsen SF, Ring HC. Secukinumab treatment of hidradenitis suppurativa: questions remain. The Lancet. 2024;403(10427):616-617. https://doi.org/10.1016/S0140-6736(23)01616-1
Author
Bibtex
@article{b1d8b5f24c184019904480667aaab71e,
title = "Secukinumab treatment of hidradenitis suppurativa: questions remain",
author = "Maul, {Julia Tatjana} and Kolios, {Antonios G.A.} and Thomsen, {Simon Francis} and Ring, {Hans Christian}",
year = "2024",
doi = "10.1016/S0140-6736(23)01616-1",
language = "English",
volume = "403",
pages = "616--617",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10427",
}
RIS
TY - JOUR
T1 - Secukinumab treatment of hidradenitis suppurativa
T2 - questions remain
AU - Maul, Julia Tatjana
AU - Kolios, Antonios G.A.
AU - Thomsen, Simon Francis
AU - Ring, Hans Christian
PY - 2024
Y1 - 2024
U2 - 10.1016/S0140-6736(23)01616-1
DO - 10.1016/S0140-6736(23)01616-1
M3 - Letter
C2 - 38368009
AN - SCOPUS:85185404644
VL - 403
SP - 616
EP - 617
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10427
ER -
ID: 384408275